Abstract:The field of cancer treatment has evolved significantly over the last decade with the emergence of next-generation therapeutic antibodies. Conventional treatments like chemotherapy pose significant challenges, including adverse side effects. Monoclonal antibodies have paved the way for more targeted and effective interventions. The evolution from chimeric to humanized and fully human antibodies has led to a reduction in immunogenicity and enhanced tolerance in vivo. The advent of next-generation antibodies, including bispecific antibodies, nanobodies, antibody-drug conjugates, glyco-engineered antibodies, and antibody fragments, represents a leap forward in cancer therapy. These innovations offer increased potency, adaptability, and reduced drug resistance. Challenges such as target validation, immunogenicity, and high production costs exist. However, technological advancements in antibody engineering techniques provide optimism for addressing these issues. The future promises a paradigm shift, where ongoing research will propel these powerful antibodies to the forefront, revolutionizing the fight against cancer and creating new preventive and curative treatments. This review provides an overview of three next-generation antibody-based molecules, namely bispecific antibodies, antibody-drug conjugates, and nanobodies that have shown promising results in cancer treatment. It discusses the evolution of antibodies from conventional forms to next-generation molecules, along with their applications in cancer treatment, production methods, and associated challenges. The review aims to offer researchers insights into the evolving landscape of next-generation antibody-based cancer therapeutics and their potential to revolutionize treatment strategies.

Antibody and antibody fragments for cancer immunotherapy

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Emerging new therapeutic antibody derivatives for cancer treatment

Genetically engineered T cells for cancer immunotherapy

Therapeutic Antibodies and Immunologic Conjugates

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications

Research Progress on Tumor-Targeting Immunoconjugate

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Cancer therapy with antibodies

Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy

The Application of the Drugs of Bispecific Antibodies in Anti-Tumor Therapy

A review of monoclonal antibody therapy for cancer and prospects

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy